Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
December 06, 2021 09:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor
December 02, 2021 08:52 ET
|
The Greater Cannabis Company, Inc.
Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies. BALTIMORE, Dec. 02, 2021 (GLOBE...
Biofrontera Inc. Announces Closing of $15 Million Private Placement
December 01, 2021 19:05 ET
|
Biofrontera Inc.
WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 30, 2021 09:20 ET
|
Biofrontera Inc.
Conference call at 4:30 p.m. Eastern time today WOBURN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Onxeo Continues to Strengthen its Board of Directors
November 23, 2021 13:08 ET
|
Onxeo S.A.
Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris (France), Nov. 23, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext...
Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
November 23, 2021 08:15 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial...
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
November 17, 2021 17:00 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG announces initiation of clinical studies
November 16, 2021 09:01 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two...
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 12, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
November 11, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov. 11, 2021...